Our work in the development of drug-loaded implants for controlled release spans more than 20 years and we have developed a proprietary drug delivery platform that can deliver active agents from a few weeks to several months, and where the release profile can be tailored for continuous or delayed release. This technology involves incorporating active compounds in polymeric delivery systems to provide extended release of the active agent. We work with both biodegradable and non-biodegradable polymers and have developed formulations for a broad range of actives including peptides and proteins. Our experience includes manufacture of biodegradable excipients, formulation and process development, and cGMP production of clinical supplies.

Drug-loaded implants consist of a mixture of an active and a polymeric excipient formed into a fiber, rod, film or other shape. The implant may be a simple monolithic mixture or may incorporate a rate-controlling membrane. Drug release is controlled by a number of variables including drug content, polymer composition and molecular weight, device geometry, and manufacturing process. DURECT’S drug-loaded implants offer many advantages for long-term delivery of active ingredients.

	Sustained, delayed, and zero-order release profiles
	Delivery times from weeks to months
	Avoidance of solvents during processing
	100% solids and high drug contents provide highest payloads possible
	Local and systemic delivery
	Robust manufacturing processes
	Extensive clinical experience
	Ability to custom make polymers

We typically work with biodegradable polymers to eliminate the need for device removal following therapy. Our DURIN technology is the basis of the DURIN-Leuprolide product intended for the treatment of Alzheimers’ Disease under license to Voyager Pharmaceutical.

To request additional information on DURIN Biodegradable Implants, please download the DURIN™ Fact Sheet (.PDF).

Back to top